4.7 Article

Prevalence of β-Lactamase-Encoding Genes among Enterobacteriaceae Bacteremia Isolates Collected in 26 US Hospitals: Report from the SENTRY Antimicrobial Surveillance Program (2010)

Journal

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 57, Issue 7, Pages 3012-3020

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.02252-12

Keywords

-

Funding

  1. American Proficiency Institute (API)
  2. Anacor
  3. Astellas
  4. AstraZeneca
  5. Bayer
  6. Cempra
  7. Cerexa
  8. Contrafect
  9. Cubist
  10. Daiichi
  11. Dipexium
  12. Enanta
  13. Furiex
  14. GlaxoSmithKline
  15. Johnson & Johnson (Ortho McNeil)
  16. LegoChem Biosciences Inc.
  17. Meiji Seika Kaisha
  18. Merck
  19. Nabriva
  20. Novartis
  21. Pfizer (Wyeth)
  22. Rempex
  23. Rib-X Pharmaceuticals
  24. Seachaid
  25. Shionogi
  26. The Medicines Co.
  27. Theravance
  28. ThermoFisher

Ask authors/readers for more resources

Enterobacteriaceae bacteremia isolates (n = 195; 6.4% overall) collected from 26 U.S. hospitals located in 20 states were screened for various beta-lactamase classes. A total of 175 isolates carried one to eight acquired beta-lactamase genes of 44 types that were detected in 55 combinations. Eighty-five (43.6%) strains carried bla(CTX-M), and bla(CTX-M-15) was the most prevalent (33.8%). Genes encoding OXA-1/30 (often associated with bla(CTX-M-15)), CMY-2, SHV extended-spectrum beta-lactamase (ESBLs), and TEM-1 were also prevalent. Among 33 carbapenem-resistant strains, 28 carried bla(KPC-2) or bla(KPC-3) (17 and 11 strains, respectively), and those were recovered mostly in the New York City area (16 strains) and Houston, TX (9 strains). Fourteen new SHV variants were identified among Klebsiella pneumoniae isolates carrying one or multiple SHV alleles, three carrying G238S and/or E240K amino acid alterations that confer ESBL activity. Only two of eight K. oxytoca isolates carried acquired beta-lactamases, but most had mutations on the bla(OXY) promoter region, and three new OXY-encoding genes were characterized. Concordance between a commercial nucleic acid-based microarray (Check-MDR CT101) and reference methods was noted for 105/109 (97.2%) strains. Thirty-two strains having genes that are not targeted by the commercial system were detected (OXA ESBLs, PER, PSE, or intrinsic genes). Overall, a great variety of enzymes were observed, with numerous strains carrying multiple genes. Rates of CTX-M-producing strains appear to be increasing in U.S. hospitals (26.6% in 2007 to 43.8% for 2010) participating in the SENTRY Program. Furthermore, the Check-Points system seems to be a reliable, robust, and user-friendly assay for detection of enzyme-mediated resistance.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available